KRYS Logo

Krystal Biotech, Inc. (KRYS) 

NASDAQ
Market Cap
$5.27B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
599 of 776
Rank in Industry
323 of 433

Largest Insider Buys in Sector

KRYS Stock Price History Chart

KRYS Stock Performance

About Krystal Biotech, Inc.

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other …

Insider Activity of Krystal Biotech, Inc.

Over the last 12 months, insiders at Krystal Biotech, Inc. have bought $0 and sold $75.5M worth of Krystal Biotech, Inc. stock.

On average, over the past 5 years, insiders at Krystal Biotech, Inc. have bought $0 and sold $47.75M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 50,000 shares for transaction amount of $1M was made by Krishnan Suma (Chief Operating Officer) on 2018‑10‑18.

List of Insider Buy and Sell Transactions, Krystal Biotech, Inc.

2024-09-12SalePresident, R&D
50,000
0.1759%
$197.77$9.89M-9.13%
2024-09-12SalePresident and CEO
50,000
0.1759%
$197.77$9.89M-9.13%
2024-06-11SalePresident, R&D
50,000
0.1734%
$175.76$8.79M+2.65%
2024-06-11SalePresident and CEO
50,000
0.1734%
$175.76$8.79M+2.65%
2024-05-20Saledirector
20,000
0.0699%
$164.13$3.28M+9.59%
2024-03-11SalePresident, R&D
50,000
0.1773%
$170.95$8.55M+3.78%
2024-03-11SalePresident and CEO
50,000
0.1773%
$170.95$8.55M+3.78%
2024-02-28SaleChief Accounting Officer
12,200
0.0438%
$165.94$2.02M+8.11%
2024-02-28SaleChief Accounting Officer
11,997
0.0431%
$165.88$1.99M+8.11%
2024-02-28SaleChief Accounting Officer
10,600
0.0381%
$166.10$1.76M+8.11%
2024-02-26SaleChief Accounting Officer
8,087
0.025%
$136.91$1.11M+12.19%
2024-01-22SaleChief Accounting Officer
2,500
0.0088%
$130.00$325,000+32.41%
2023-12-11SalePresident, R&D
50,000
0.1761%
$105.67$5.28M+60.09%
2023-12-11SalePresident and CEO
50,000
0.1761%
$105.67$5.28M+60.09%
2023-09-11SalePresident, R&D
50,000
0.1769%
$127.23$6.36M+20.36%
2023-09-11SalePresident and CEO
50,000
0.1769%
$127.23$6.36M+20.36%
2023-06-09Saledirector
18,935
0.0736%
$128.77$2.44M-4.32%
2023-06-09SaleChief Commercial Officer
12,500
0.0485%
$128.61$1.61M-4.32%
2023-06-08Saledirector
31,065
0.1209%
$128.11$3.98M-3.61%
2023-05-31SalePresident, R&D
50,000
0.1917%
$116.20$5.81M+4.58%

Insider Historical Profitability

54.51%
Krishnan Krish SPresident and CEO
1500882
5.2241%
$183.58324+37.18%
Krishnan SumaPresident, R&D
1500882
5.2241%
$183.58427+56.24%
JANNEY DANIELdirector
107362
0.3737%
$183.5818+1.89%
NORBY R DOUGLASdirector
9000
0.0313%
$183.5810+106.7%
Riley Antony AChief Financial Officer
2800
0.0097%
$183.5810+100%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$755.12M14.864.24M+77.87%+$330.59M0.05
Avoro Capital Advisors Llc$454.71M8.952.56M-0.39%-$1.78M5.45
The Vanguard Group$432.86M8.522.43M-0.12%-$532,900.350.01
BlackRock$321.23M6.321.81M-0.23%-$741,612.240.01
Redmile Group$268.36M5.281.51M-12.98%-$40.02M2.74
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.